Daily oral tenofovir-based PrEP is just the beginning. Today’s research pipeline includes many other ARV-based prevention tools. Some of these, like the dapivirine vaginal ring are under regulatory consideration. Long-acting injectable PrEP is in efficacy trials. A range of other strategies, including multipurpose prevention products that could protect against HIV as well as other STIs and/or pregnancy are also in development.
More primary prevention tools mean more choice, and history shows that this means more use of all products. Learn more about the status of tomorrow’s strategies here: